Trial | NCT02592941  Report issue

Title

Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
An Open Label, Expanded Access Protocol Intended to Provide Treatment With MP-104 (Deflazacort) to U.S. Children, Adolescents, and/or Adults With Duchenne Muscular Dystrophy

  • Phase

    N/A

  • Study Type

    Expanded Access

  • Status

    Approved for marketing

  • Study Participants

    None
The expanded access program will provide access to treatment with deflazacort in children, adolescent, and adult patients with DMD in the U.S. who are ineligible, unable, or otherwise unwilling to enroll in a clinical study examining the efficacy of deflazacort while a new drug application is under preparation and review. Enrollment is open to all eligible patients.
Deflazacort will be supplied free of charge and shipped directly to patients or caregivers, as appropriate. Treating physicians will continue to follow their standard of care activities and procedures for management of DMD. Treating physicians participating in the expanded access program are required to collect/document any patient or caregiver reported safety events and report to the sponsor..
Study Started
Oct 29
2015
Last Update
Feb 28
2018

Drug Deflazacort

Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.

  • Other names: DFZ

Criteria 

Main Inclusion Criteria:

Confirmed diagnosis of Duchenne muscular dystrophy
The patient is ≥ 5 years old
Current on all childhood vaccinations including the chicken pox vaccine

Main Exclusion Criteria:

History or current medication condition that could affect safety or poses an additional risk
Hypersensitivity or allergic reaction to steroids or their formulations
No Results Posted